<DOC>
	<DOCNO>NCT00200343</DOCNO>
	<brief_summary>This study 24-week multicenter , randomize , double-blind control trial ursodeoxycholic acid ( UDCA ) patient chronic hepatitis C Japan . The primary objective study verify superiority efficacy UDCA 600 900mg/day 150mg/day safety UDCA treatment .</brief_summary>
	<brief_title>Efficacy Safety Study Ursodeoxycholic Acid Treat Chronic Hepatitis C</brief_title>
	<detailed_description>This study 24-week multicenter , randomize , double-blind control trial ursodeoxycholic acid ( UDCA ) patient chronic hepatitis C Japan . The primary objective study verify superiority efficacy UDCA 600 900mg/day 150mg/day safety UDCA treatment . The primary endpoint percent change serum alanine aminotransferase ( ALT ) level 24-week administration compare pre-administration level secondary endpoint , serum aspartate aminotransferase ( AST ) gamma-glutamyltranspeptidase ( gamma-GTP ) level . Further , change bile acid composition HCV-RNA level 24-week administration examine .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Subject must clinical diagnosis apply conservative medication chronic hepatitis C. 2 . Serum alanine aminotransferase level measure 4week initiation treatment must 61 IU/mL . 3 . Subject 's age must 20 year old . 1 . Subject receive treatment antiviral agent ( interferon ) within 20 week start 8week observation period 2 . Subject receive treatment corticosteroid , immunosuppressive drug , glycyrrhizic acid , cholestyramine drug could interfere hepatic function 8week observation period . 3 . Subject decompensated cirrhosis 4 . Subject infect hepatic virus 5 . Subject receive treatment autoimmune disease , alcohol druginduced hepatic disorder , neoplasia , hepatocholangiolar disease , fulminant hepatitis peptic ulcer 6 . Subject require hospitalization complication heart , kidney pancreas 7 . Pregnancy 8 . Alcoholics 9 . Alcohol intake 27 ml/day 10 . Subject involved clinical trial within 4 week start observation period 11 . Subject history sensitivity ursodeoxycholic acid bile acidproducts</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic hepatitis C , Ursodeoxycholic acid</keyword>
</DOC>